Amylin's $203M Offering to Support Bydureon Launch
By Catherine Shaffer
Friday, March 9, 2012
Compared with getting the drug approved in the first place, raising more than $200 million to fund its commercialization is a snap.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.